Elicio Therapeutics (ELTX) Non-Current Assets (2020 - 2026)

Elicio Therapeutics (ELTX) has reported Non-Current Assets for 7 consecutive years, with $5.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non-Current Assets fell 15.66% year-over-year to $5.8 million; the trailing twelve-month figure through Jun 2026 stood at $25.7 million (down 12.47% YoY), and the FY2025 full-year result was $6.6 million, down 12.48% from the prior year.
• Non-Current Assets eased to $5.8 million in Q2 2026 per ELTX's latest filing, from $6.5 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $11.9 million in Q4 2022 and bottomed at $1.1 million in Q1 2023.
• Historically, Non-Current Assets has averaged $7.5 million across 5 years, with a median of $7.1 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Non-Current Assets slumped 77.29% in 2023, then jumped 807.89% in 2024.
• Over 5 years, Non-Current Assets stood at $11.9 million in 2022, then dropped by 9.62% to $10.8 million in 2023, then sank by 30.68% to $7.5 million in 2024, then dropped by 12.48% to $6.6 million in 2025, then declined by 10.78% to $5.8 million in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $5.8 million, $6.5 million, and $6.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.